Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 2 Participants’ percentage of abstinence during maintenance dose period (Missing = Positive)

From: Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder

Participants’ percentage of abstinence

Maintenance dose groups

BUP-XR 300/300 mg

BUP-XR 300/100 mg

Difference (95% CI)a 300–100 mg

P valueb

Opioid-injecting participants

N

63

66

  

Weeks 10–25

Unadjusted

Mean (SE)

58.2% (4.62%)

44.0% (4.75%)

14.20% (1.22, 27.18%)

0.0320

Risk adjusted

Mean (SE)

59.6% (5.19%)

46.6% (5.34%)

13.04% (− 1.56, 27.64%)

0.0800

Weeks 14–25

Unadjusted

Mean (SE)

59.5% (4.79%)

42.6% (4.78%)

16.97% (3.71, 30.24%)

0.0122

Risk adjusted

Mean (SE)

61.5% (5.35%)

45.0% (5.40%)

16.48% (1.58, 31.37%)

0.0074

Weeks 18–25

Unadjusted

Mean (SE)

60.7% (4.85%)

42.0% (4.83%)

18.67% (5.25, 32.09%)

0.0064

Risk adjusted

Mean (SE)

62.9% (5.26%)

44.2% (5.39%)

18.65% (3.90, 33.41%)

0.0132

Non-injecting opioid participants

N

92

90

  

Weeks 10–25

Unadjusted

Mean (SE)

46.6% (4.22%)

56.3% (3.99%)

− 9.65% (− 21.03, 1.73)

0.0966

Risk adjusted

Mean (SE)

44.2% (4.56%)

54.3% (4.19%)

− 10.06% (− 22.20, 2.08)

0.1044

Weeks 14–25

Unadjusted

Mean (SE)

46.0% (4.41%)

54.9% (4.19%)

− 8.89% (− 20.81, 3.02)

0.1435

Risk adjusted

Mean (SE)

43.3% (4.78%)

53.0% (4.33%)

− 9.66% (− 22.31, 2.99)

0.1343

Weeks 18–25

Unadjusted

Mean (SE)

45.2% (4.55%)

53.8% (4.28%)

− 8.51% (− 20.75, 3.74)

0.1735

Risk adjusted

Mean (SE)

42.4% (4.91%)

51.8% (4.40%)

− 9.41% (− 22.34, 3.52)

0.1536

  1. N No. of participants in the analysis set
  2. Each participant’s percentage abstinence was calculated after the first (weeks 10–25), second (weeks 14–25), and third (weeks 18–25) maintenance doses as the proportion (%) of negative opioid use results among the corresponding 16, 12, and 8 weekly assessments, respectively. Missing = Positive: the missing UDS or missing self-report for illicit opioid use at a specific scheduled visit was imputed as positive for that visit. The risk-adjusted analysis compared the 100-mg versus 300-mg maintenance dose groups via inverse propensity weighting using propensity scores
  3. CI confidence interval, SE standard error, UDS urine drug screen
  4. aGroup mean (SE) and 95% CI of difference in group mean was based on the general linear model Robust Sandwich variance estimator
  5. bP value was based on the Wald test